Recruiting cancer drug studies
There are several clinical cancer drug trials going on in the Eastern collaborative area. Clinical drug trials offer the possibility to receive new treatments, which are not yet available outside of trials.
You can find a list of ongoing cancer drug trials in the Eastern collaborative are below. The trials are listed according to cancer type.
If you are interested in taking part in an ongoing study, or you wish to know more about cancer research, please contact your treating doctor or the contact person of the study.
Prostate cancer
| OMAHA MK5684-003 |
| Research design: A randomized, open label phase 3 study, which trials MK-5684 in comparison to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer. Target group: Patients with metastatic castration-resistant prostate cancer, who have previously been treated with new hormone drugs (NHA novel hormonal agents) and taxane-based cytostatic drugs. ClinicalTrials.gov: NCT06136624 Contact information: tutkimuspotilaaksi@pshyvinvointialue.fi |
| KupsMA-Lu177 |
| Research design: The study investigates the effectiveness and safety, as well as the factors predicting treatment response, of the Lutetium-177 treatment in patients with metastatic castration-resistant prostate cancer. Target group: Patients with metastatic castration-resistant prostate cancer, which has spread despite second-generation hormonal drug treatment (abiraterone or enzalutamide). Contact information: Okko Kääriäinen okko.kaariainen@pshyvinvointialue.fi |
| MevPro-2 |
Research design: A phase 3, randomized, double-blind and placebo-controlled study, which investigates the use of the drug PF06821497 (mevrometostat) together with enzalutamide.
Target group: Men with metastatic castration-resistant prostate cancer, who have not previously received a new type of hormone treatment or chemotherapy as a treatment for metastatic prostate cancer.
ClinicalTrials.gov: NCT06629779
Contact information: tutkimuspotilaaksi@pshyvinvointialue.fi
Gynecological cancers
| UTERINE CANCER |
| PETREC Research design: A randomized, national multicenter study for patients with endometrial cancer, which compares the effectiveness of chemotherapy to the combination of chemotherapy and external pelvic radiotherapy in p53 abn-subgroup and non-endometrioid cancers, and the effectiveness of internal vaginal radiotherapy to external pelvic radiotherapy in MMR-D and NSMP subgroups. Target group: Women with molecularly categorized high-intermediate or high-risk endometrial carcinoma, which has spread to stage I or II. Contact information: Elina Puumalainen elina.puumalainen@pshyvinvointialue.fi Jatta Salomaa jatta.salomaa@pshyvinvointialue.fi |
| OVARIAN CANCER |
| HERO Research design: An on-going long-term follow-up study on the classification of ovarian cancer patients based on HR-status. The study investigates factors which may predict the results of short- or long-term treatment of ovarian cancer. Target group: Patients with ovarian cancer. ClinicalTrials.gov: NCT03085095 Contact information: Elina Puumalainen elina.puumalainen@pshyvinvointialue.fi Jatta Salomaa jatta.salomaa@pshyvinvointialue.fi |
Keuhkosyöpä
| Lung-301 Research design: A phase study, which assesses the effectiveness and safety of dostarlimab combined with belrestotug in comparison to pembrolizumab combined with a placebo drug. Target group: Patients, who have previously untreated, inoperable, locally spread or metastatic lung cancer. ClinicalTrials.gov: NCT06472076 Contact information: tutkimuspotilaaksi@pshyvinvointialue.fi |
| Krascendo-1 Research design: An open, phase 3 multicenter study, which assesses the effectiveness and safety of divarasib in comparison to sotorasib or adagrasib. Target group: Patients, who have previously treated KRAS G12C-positive and advanced or metastatic non-small cell lung cancer. ClinicalTrials.gov: NCT06497556 Contact information: tutkimuspotilaaksi@pshyvinvointialue.fi |
Leukemia
| BEXMAB (adult leukemia) Research design: A phase 2-3 open study on the tolerability, safety and preliminary effectiveness of bexmarilimab in combination with azacitidine or azacitidine and venetoclax. Target group: Patients, who have myelodysplastic syndrome, chronic myelomonocytic leukemia, acute myeloid leukemia or renewed acute myeloid leukemia. ClinicalTrials.gov: NCT05428969 Contact information: Marja Pyörälä marja.pyorala@pshyvinvointialue.fi |
| ALLTogether1 Research design: A phase 3 study, which aims to provide more individualized leukemia treatment, enable new innovative treatments (targeted antibody treatments, CAR-T cell therapy) for patients for whom the traditional chemotherapy has not been sufficient, and reduce the side effects of treatments on patients with good prognosis. Target group: Treatment program for patients aged 1-45 with acute lymphoblastic leukemia. ClinicalTrials.gov: NCT04307576 Contact information: adults: Asta Kuosmanen asta.kuosmanen@pshyvinvointialue.fi children: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
Lymphoma
| INCMOR 0208-305 Research design: A phase 3 study, which aims to assess the effectiveness and safety of tafasitamab and lenalidomide. Target group: Patients with has with relapsed or refractory diffuse large B-Cell lymphoma (DLBCL). ClinicalTrials.gov: NCT04680052 Contact information: Outi Kuittinen outi.kuittinen@uef.fi |
| GOLSEEK-1 Research design: A phase 3 study, which aims to compare the effectiveness and safety of golcadomide combined with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy in comparison to a placebo drug combined with R-CHOP chemotherapy. Target group: Patients, who have high risk large cell B-cell lymphoma (LBCL), which has not previously been treated. ClinicalTrials.gov: NCT06356129 Contact information: Outi Kuittinen outi.kuittinen@uef.fi |
| MERLIN Research design: A phase 2 study, in which the study drug mosunetuzumab is given to patients whose follicular lymphoma has renewed or spread within 24 months after the start of first-line treatment. Target group: Patients whose follicular lymphoma has renewed or spread within 24 months after the start of first-line treatment. ClinicalTrials.gov: NCT05849857 Contact information: Annikki Aromaa-Häyhä annikki.aromaa-hayha@pshyvinvointialue.fi |
| POLARBEAR Research design: A phase 3 study, which investigates the effectiveness of polatuzumab vedotin combined with R-mini-chop treatment. Target group: Patients over 75 years old, who have been diagnosed with diffuse large cell B-cell lymphoma. ClinicalTrials.gov: NCT04332822 Contact information: Okko Kääriäinen okko.kaariainen@pshyvinvointialue.fi |
Myeloma
| Successor-1 Research design: Phase 3 randomized multicenter study, which compares the combination treatment of CC-92480, bortezomib and dexamethasone with the combination treatment of pomalidomide, bortezomib and dexamethasone. Target group: Patients with multiple myeloma which has recurred or does not respond to treatment. ClinicalTrials.gov: NCT05519085 Contact information: Anu Partanen anu.partanen@pshyvinvointialue.fi |
| IM048022 Research design: Phase 3 randomized controlled multicenter study, where the effectiveness of iberdomide is compared with lenalidomide in the maintenance treatment of patients who have received an autologous stem cell transplant as first-line treatment. Target group: Patients, who have received an autologous stem cell transplant as first-line treatment. ClinicalTrials.gov: NCT05827016 Contact information: Anu Partanen anu.partanen@pshyvinvointialue.fi |
| MagnetisMM32 Research design: Phase 3 study, which compares elranatamab monotherapy to elotuzumab, pomalidomide and dexamethasone (EPd) or pomalidomide, bortezomib and dexamethasone (PVd) combinations, or a carfilzomib and dexamethasone (Kd) combination. Target group: Patients with multiple myeloma which has recurred or does not respond to treatment, and who have previously received CD38 antibody treatment. ClinicalTrials.gov: NCT06152575 Contact information: Anu Partanen anu.partanen@pshyvinvointialue.fi |
Breast cancer
| pionERA C044657 Research design: A phase 3 open, randomized trial, which assesses the effectiveness and safety of giredestrant in comparison to fulvestrant, when both are used in combination with a CDK4/6 inhibitor. Target group: Patients with estrogen receptor -positive and HER2-negative advanced breast cancer, who have not responded to previous adjuvant endocrine therapy. ClinicalTrials.gov: NCT06065748 Contact information: tutkimuspotilaaksi@pshyvinvointialue.fi |
Bile duct cancer / gallbladder cancer
| Jazz Research design: Phase 3 drug trial, which compares the effectiveness of zanidatamb to standard treatment in patients with metastatic or locally spread bile duct/gallbladder cancer with HER2-positive tumors. Target group: Patients with metastatic or locally spread bile duct/gallbladder cancer with HER2-positive tumors. ClinicalTrials.gov: NCT06282575 Contact information: tutkimuspotilaaksi@pshyvinvointialue.fi |
Children’s cancers
| LEUKEMIA |
| Interfant21 International treatment program for children under the age of 1, who have been diagnosed with acute lymphoblastic or mixed-phenotype leukemia related to the rearranged KMT2A gene. ClinicalTrials.gov: NCT05327894 Contact information: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
| ALLTogether1 Research design: A phase 3 clinical trial, which aims to provide a more personalized treatment for leukemia through innovative treatments (targeted antibody treatments, CAR-T-cell therapy) for patients for whom traditional chemotherapy is not sufficient. Simultaneously, it aims to reduce the side effects of treatments on patients with good disease prognosis. Target group: Treatment research program for acute lymphoblastic leukemia patients between the ages of 1-45. ClinicalTrials.gov: NCT04307576 Contact information: adults: Asta Kuosmanen asta.kuosmanen@pshyvinvointialue.fi children: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
| IntReALL HR International treatment study on high risk recurrent childhood lymphoblastic leukemia. ClinicalTrials.gov: NCT03590171 Contact information: Jouni Pesola jouni.pesola@pshyvinvointialue.fi |
| EsPhALL2017 A phase 3 clinical trial with two alternative chemotherapy programs and an imatinib drug. Participants are children and adolescents who suffer from Philadelphia-positive acute lymphoblastic leukemia. ClinicalTrials.gov: NCT03007147 Contact information: Jouni Pesola jouni.pesola@pshyvinvointialue.fi |
| B-NHL 2013 European treatment and research program for in children and adolescents. Lapsuus- ja nuoruusiän kypsän aggressiivisen B-solulymfooman ja Burkittin leukemian eurooppalainen hoito- ja tutkimusohjelma. Tutkimuksessa selvitetään, säilyykö ennuste yhtä hyvänä, jos perinteiset sydämelle haitalliset solunsalpaajat korvataan rituksimabilla (anti CD 20-vasta-aine) riskiryhmissä R1 ja R2. Levinneimpien tautimuotojen (R3 ja R4 riskiryhmät) osalta verrataan, paraneeko tautivapaa elossapysyminen lisäämällä rituximabi hoitoon solunsalpaajahoidon rinnalle. ClinicalTrials.gov: NCT03206671 Contact information: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
| CHILDREN’S BRAIN TUMORS |
| Ependymooma SIOP International clinical program for the diagnosis and treatment of children’s, adolescent’s and young adult’s ependymoma. EudraCT number: 2013-002766-39 Contact information: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
| LYMFOOMA |
| LBL 2018 An international lymphoblastic lymphoma treatment program for children and adolescents. The key difference between the LBL2018 -treatment program and existing treatments is the more precise risk group classification, which guides in choosing the treatment intensity. The risk group classification (standard risk / high risk) is based on the extent to which the disease has spread, as well as the immunophenotype of the tumor and genetic findings (e.g. NOTCH1 + FBXW7 mutations). ClinicalTrials.gov: NCT04043494 Contact information: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
| ALCL International drug study on the effectiveness of vinblastine treatment in children and adolescents under 18 years old, who have standard risk alk-positive ALCL. Contact information: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
| B-NHL 2013 European research and treatment program for childhood and adolescent mature aggressive B-cell lymphoma and Burkitt leukemia. The study investigates whether the prognosis of the disease remains equally good if traditional chemotherapy drugs, which are harmful for the heart, are replaced with rituximab (CD20 antibody) in risk groups R1 and R2. In more widely spread forms of the disease (risk groups R3 and R4), the study investigates whether disease-free survival is increased by adding rituximab to the treatment in combination with chemotherapy. ClinicalTrials.gov: NCT03206671 Contact information: Kaisa Vepsäläinen kaisa.vepsalainen@pshyvinvointialue.fi |
Other cancers
| FINPROVE: Personal cancer treatment in different tumor types Research design: The study investigates the effect of cancer treatment on advanced cancer, where standard treatments have proven inefficient. The tumors are analyzed for DNA and RNA transformations, which is used as the basis for deciding on the patient’s drug treatment. Target group: Patients, whose tumor has a molecular transformation fitting the study’s drug range. ClinicalTrials.gov: NCT05159245 Contact information: Okko Kääriäinen okko.kaariainen@pshyvinvointialue.fi |
Fimea provides a listing of recruiting drug studies, which is meant to inform both patients and health care professional about open clinical drug trials in Finland. The studies are listed according to disease type. The listing is not yet fully comprehensive for cancer drug trials.
Clinical trials looking for participants – (Fimea.fi) (in Finnish)
